Erratum: Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma (Cell (2018) 175(4) (998–1013.e20), (S0092867418313941) (10.1016/j.cell.2018.10.038));Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

Cell

Volumn 175, Issue 4, 2018, Pages 998-1013.e20

  Sade Feldman, Moshe ^a,b   Yizhak, Keren ^b   Bjorgaard, Stacey L ^a,b   Ray, John P ^b   de Boer, Carl G ^b   Jenkins, Russell W ^a,c   Lieb, David J ^b   Chen, Jonathan H ^a,b   Frederick, Dennie T ^a   Barzily Rokni, Michal ^a   Freeman, Samuel S ^a,b   Reuben, Alexandre ^d   Hoover, Paul J ^b,e   Villani, Alexandra Chloé ^a,b   Ivanova, Elena ^a,c   Portell, Andrew ^a,c   Lizotte, Patrick H ^a,c   Aref, Amir R ^a,c   Eliane, Jean Pierre ^a   Hammond, Marc R ^a   Vitzthum, Hans ^a   Blackmon, Shauna M ^a   Li, Bo ^a,b   Gopalakrishnan, Vancheswaran ^d   Reddy, Sangeetha M ^d   Cooper, Zachary A ^d   Paweletz, Cloud P ^a,c   Barbie, David A ^a   Stemmer Rachamimov, Anat ^a   Flaherty, Keith T ^a   Wargo, Jennifer A ^d   Boland, Genevieve M ^a   Sullivan, Ryan J ^a   Getz, Gad ^a,b   Hacohen, Nir ^a,b   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

cancer immunotherapy; CD8+ T cells; checkpoint blockade; single cell RNA seq; TCF7

Indexed keywords

ANTINEOPLASTIC AGENT; CD39 ANTIGEN; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; TCF7 PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CHROMATIN; CLINICAL ARTICLE; CLINICAL OUTCOME; CLONAL VARIATION; COHORT ANALYSIS; CONTROLLED STUDY; EPIGENETICS; FEMALE; HUMAN; HUMAN CELL; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA SEQUENCE; SINGLE CELL RNA SEQUENCING; SURVIVAL; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR REGRESSION;

EID: 85055560004     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2018.12.034     Document Type: Erratum

References (69)

1. Allard, B., Pommey, S., Smyth, M.J., Stagg, J., Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin. Cancer Res. 19 (2013), 5626–5635.
2. Anderson, A.C., Joller, N., Kuchroo, V.K., Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. Immunity 44 (2016), 989–1004.
3. Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D.R., Albright, A., Cheng, J.D., Kang, S.P., Shankaran, V., et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127 (2017), 2930–2940.
4. Bastid, J., Regairaz, A., Bonnefoy, N., Déjou, C., Giustiniani, J., Laheurte, C., Cochaud, S., Laprevotte, E., Funck-Brentano, E., Hemon, P., et al. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity. Cancer Immunol. Res. 3 (2015), 254–265.
5. Bolotin, D.A., Poslavsky, S., Mitrophanov, I., Shugay, M., Mamedov, I.Z., Putintseva, E.V., Chudakov, D.M., MiXCR: software for comprehensive adaptive immunity profiling. Nat. Methods 12 (2015), 380–381.
6. Callahan, M.K., Postow, M.A., Wolchok, J.D., Targeting T Cell Co-receptors for Cancer Therapy. Immunity 44 (2016), 1069–1078.
7. + T Cells. Cancer Res. 78 (2018), 115–128.
8. Carpenter, A.E., Jones, T.R., Lamprecht, M.R., Clarke, C., Kang, I.H., Friman, O., Guertin, D.A., Chang, J.H., Lindquist, R.A., Moffat, J., et al. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol., 7, 2006, R100.
9. Chen, P.L., Roh, W., Reuben, A., Cooper, Z.A., Spencer, C.N., Prieto, P.A., Miller, J.P., Bassett, R.L., Gopalakrishnan, V., Wani, K., et al. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 6 (2016), 827–837.
10. Cibulskis, K., Lawrence, M.S., Carter, S.L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E.S., Getz, G., Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31 (2013), 213–219.
11. Cibulskis, K., McKenna, A., Fennell, T., Banks, E., DePristo, M., Getz, G., ContEst: estimating cross-contamination of human samples in next-generation sequencing data. Bioinformatics 27 (2011), 2601–2602.
12. Corces, M.R., Buenrostro, J.D., Wu, B., Greenside, P.G., Chan, S.M., Koenig, J.L., Snyder, M.P., Pritchard, J.K., Kundaje, A., Greenleaf, W.J., et al. Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution. Nat. Genet. 48 (2016), 1193–1203.
13. Costello, M., Pugh, T.J., Fennell, T.J., Stewart, C., Lichtenstein, L., Meldrim, J.C., Fostel, J.L., Friedrich, D.C., Perrin, D., Dionne, D., et al. Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation. Nucleic Acids Res., 41, 2013, e67.
14. Daud, A.I., Loo, K., Pauli, M.L., Sanchez-Rodriguez, R., Sandoval, P.M., Taravati, K., Tsai, K., Nosrati, A., Nardo, L., Alvarado, M.D., et al. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J. Clin. Invest. 126 (2016), 3447–3452.
15. Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., Gingeras, T.R., STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29 (2013), 15–21.
16. Eisenhauer, E.A., Therasse, P., Bogaerts, J., Schwartz, L.H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45 (2009), 228–247.
17. Ellrott, K., Bailey, M.H., Saksena, G., Covington, K.R., Kandoth, C., Stewart, C., Hess, J., Ma, S., Chiotti, K.E., McLellan, M., et al. Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Cell Syst 6 (2018), 271–281.e7.
18. Fuertes Marraco, S.A., Neubert, N.J., Verdeil, G., Speiser, D.E., Inhibitory Receptors Beyond T Cell Exhaustion. Front. Immunol., 6, 2015, 310.
19. Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313 (2006), 1960–1964.
20. Gao, J., Shi, L.Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S.E., et al. Loss of IFN-gamma Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell 167 (2016), 397–404.e9.
21. Gattinoni, L., Zhong, X.S., Palmer, D.C., Ji, Y., Hinrichs, C.S., Yu, Z., Wrzesinski, C., Boni, A., Cassard, L., Garvin, L.M., et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat. Med. 15 (2009), 808–813.
22. Granek, J.A., Clarke, N.D., Explicit equilibrium modeling of transcription-factor binding and gene regulation. Genome Biol., 6, 2005, R87.
23. Gupta, P.K., Godec, J., Wolski, D., Adland, E., Yates, K., Pauken, K.E., Cosgrove, C., Ledderose, C., Junger, W.G., Robson, S.C., et al. CD39 Expression Identifies Terminally Exhausted CD8+ T Cells. PLoS Pathog., 11, 2015, e1005177.
24. Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y.C., Laslo, P., Cheng, J.X., Murre, C., Singh, H., Glass, C.K., Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38 (2010), 576–589.
25. Huang, A.C., Postow, M.A., Orlowski, R.J., Mick, R., Bengsch, B., Manne, S., Xu, W., Harmon, S., Giles, J.R., Wenz, B., et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545 (2017), 60–65.
26. Hugo, W., Zaretsky, J.M., Sun, L., Song, C., Moreno, B.H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell 165 (2016), 35–44.
27. Hurton, L.V., Singh, H., Najjar, A.M., Switzer, K.C., Mi, T., Maiti, S., Olivares, S., Rabinovich, B., Huls, H., Forget, M.A., et al. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc. Natl. Acad. Sci. USA 113 (2016), E7788–E7797.
28. Im, S.J., Hashimoto, M., Gerner, M.Y., Lee, J., Kissick, H.T., Burger, M.C., Shan, Q., Hale, J.S., Lee, J., Nasti, T.H., et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature 537 (2016), 417–421.
29. Jenkins, R.W., Aref, A.R., Lizotte, P.H., Ivanova, E., Stinson, S., Zhou, C.W., Bowden, M., Deng, J., Liu, H., Miao, D., et al. Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov. 8 (2018), 196–215.
30. Langmead, B., Salzberg, S.L., Fast gapped-read alignment with Bowtie 2. Nat. Methods 9 (2012), 357–359.
31. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Cowey, C.L., Lao, C.D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N. Engl. J. Med. 373 (2015), 23–34.
32. Li, B., Dewey, C.N., RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics, 12, 2011, 323.
33. Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., 1000 Genome Project Data Processing Subgroup. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25 (2009), 2078–2079.
34. Lois, C., Hong, E.J., Pease, S., Brown, E.J., Baltimore, D., Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 295 (2002), 868–872.
35. Maaten, L.v.d., Hinton, G., Visualizing Data using t-SNE. J Machine Learning Research 9 (2008), 2579–2605.
36. Mahmoud, S.M., Paish, E.C., Powe, D.G., Macmillan, R.D., Grainge, M.J., Lee, A.H., Ellis, I.O., Green, A.R., Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J. Clin. Oncol. 29 (2011), 1949–1955.
37. Mami-Chouaib, F., Blanc, C., Corgnac, S., Hans, S., Malenica, I., Granier, C., Tihy, I., Tartour, E., Resident memory T cells, critical components in tumor immunology. J. Immunother. Cancer, 6, 2018, 87.
38. McGranahan, N., Rosenthal, R., Hiley, C.T., Rowan, A.J., Watkins, T.B.K., Wilson, G.A., Birkbak, N.J., Veeriah, S., Van Loo, P., Herrero, J., Swanton, C., TRACERx Consortium. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell 171 (2017), 1259–1271.e11.
39. McLean, C.Y., Bristor, D., Hiller, M., Clarke, S.L., Schaar, B.T., Lowe, C.B., Wenger, A.M., Bejerano, G., GREAT improves functional interpretation of cis-regulatory regions. Nat. Biotechnol. 28 (2010), 495–501.
40. Paley, M.A., Kroy, D.C., Odorizzi, P.M., Johnnidis, J.B., Dolfi, D.V., Barnett, B.E., Bikoff, E.K., Robertson, E.J., Lauer, G.M., Reiner, S.L., Wherry, E.J., Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science 338 (2012), 1220–1225.
41. Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12 (2012), 252–264.
42. Philip, M., Fairchild, L., Sun, L., Horste, E.L., Camara, S., Shakiba, M., Scott, A.C., Viale, A., Lauer, P., Merghoub, T., et al. Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature 545 (2017), 452–456.
43. Picelli, S., Björklund, A.K., Faridani, O.R., Sagasser, S., Winberg, G., Sandberg, R., Smart-seq2 for sensitive full-length transcriptome profiling in single cells. Nat. Methods 10 (2013), 1096–1098.
44. Prat, A., Navarro, A., Paré L., Reguart, N., Galván, P., Pascual, T., Martínez, A., Nuciforo, P., Comerma, L., Alos, L., et al. Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. Cancer Res. 77 (2017), 3540–3550.
45. Qiu, X., Mao, Q., Tang, Y., Wang, L., Chawla, R., Pliner, H.A., Trapnell, C., Reversed graph embedding resolves complex single-cell trajectories. Nat. Methods 14 (2017), 979–982.
46. Ramos, A.H., Lichtenstein, L., Gupta, M., Lawrence, M.S., Pugh, T.J., Saksena, G., Meyerson, M., Getz, G., Oncotator: cancer variant annotation tool. Hum. Mutat. 36 (2015), E2423–E2429.
47. Riaz, N., Havel, J.J., Makarov, V., Desrichard, A., Urba, W.J., Sims, J.S., Hodi, F.S., Martin-Algarra, S., Mandal, R., Sharfman, W.H., et al. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell 171 (2017), 934–949.e15.
48. Rizvi, N.A., Hellmann, M.D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J.J., Lee, W., Yuan, J., Wong, P., Ho, T.S., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 (2015), 124–128.
49. Robert, C., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, L., Daud, A., Carlino, M.S., McNeil, C., Lotem, M., et al., KEYNOTE-006 investigators. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N. Engl. J. Med. 372 (2015), 2521–2532.
50. Robinson, M.D., McCarthy, D.J., Smyth, G.K., edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26 (2010), 139–140.
51. Sade-Feldman, M., Jiao, Y.J., Chen, J.H., Rooney, M.S., Barzily-Rokni, M., Eliane, J.P., Bjorgaard, S.L., Hammond, M.R., Vitzthum, H., Blackmon, S.M., et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat. Commun., 8, 2017, 1136.
52. Sen, D.R., Kaminski, J., Barnitz, R.A., Kurachi, M., Gerdemann, U., Yates, K.B., Tsao, H.W., Godec, J., LaFleur, M.W., Brown, F.D., et al. The epigenetic landscape of T cell exhaustion. Science 354 (2016), 1165–1169.
53. Sharma, P., Shen, Y., Wen, S., Yamada, S., Jungbluth, A.A., Gnjatic, S., Bajorin, D.F., Reuter, V.E., Herr, H., Old, L.J., Sato, E., CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc. Natl. Acad. Sci. USA 104 (2007), 3967–3972.
54. Shum, T., Omer, B., Tashiro, H., Kruse, R.L., Wagner, D.L., Parikh, K., Yi, Z., Sauer, T., Liu, D., Parihar, R., et al. Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells. Cancer Discov. 7 (2017), 1238–1247.
55. Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J.M., Desrichard, A., Walsh, L.A., Postow, M.A., Wong, P., Ho, T.S., et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371 (2014), 2189–2199.
56. Speiser, D.E., Ho, P.C., Verdeil, G., Regulatory circuits of T cell function in cancer. Nat. Rev. Immunol. 16 (2016), 599–611.
57. Spitzer, M.H., Carmi, Y., Reticker-Flynn, N.E., Kwek, S.S., Madhireddy, D., Martins, M.M., Gherardini, P.F., Prestwood, T.R., Chabon, J., Bendall, S.C., et al. Systemic Immunity Is Required for Effective Cancer Immunotherapy. Cell 168 (2017), 487–502.e15.
58. Sun, X., Wu, Y., Gao, W., Enjyoji, K., Csizmadia, E., Müller, C.E., Murakami, T., Robson, S.C., CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice. Gastroenterology 139 (2010), 1030–1040.
59. Tirosh, I., Izar, B., Prakadan, S.M., Wadsworth, M.H. 2nd, Treacy, D., Trombetta, J.J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352 (2016), 189–196.
60. Tumeh, P.C., Harview, C.L., Yearley, J.H., Shintaku, I.P., Taylor, E.J., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515 (2014), 568–571.
61. Utzschneider, D.T., Charmoy, M., Chennupati, V., Pousse, L., Ferreira, D.P., Calderon-Copete, S., Danilo, M., Alfei, F., Hofmann, M., Wieland, D., et al. T Cell Factor 1-Expressing Memory-like CD8(+) T Cells Sustain the Immune Response to Chronic Viral Infections. Immunity 45 (2016), 415–427.
62. Van Allen, E.M., Miao, D., Schilling, B., Shukla, S.A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Foppen, M.H.G., Goldinger, S.M., et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350 (2015), 207–211.
63. Villani, A.C., Satija, R., Reynolds, G., Sarkizova, S., Shekhar, K., Fletcher, J., Griesbeck, M., Butler, A., Zheng, S., Lazo, S., et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science, 356, 2017, eaah4573.
64. Waugh, K.A., Leach, S.M., Moore, B.L., Bruno, T.C., Buhrman, J.D., Slansky, J.E., Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model. J. Immunol. 197 (2016), 1477–1488.
65. Weirauch, M.T., Yang, A., Albu, M., Cote, A.G., Montenegro-Montero, A., Drewe, P., Najafabadi, H.S., Lambert, S.A., Mann, I., Cook, K., et al. Determination and inference of eukaryotic transcription factor sequence specificity. Cell 158 (2014), 1431–1443.
66. Wherry, E.J., Ha, S.J., Kaech, S.M., Haining, W.N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J.N., Barber, D.L., Ahmed, R., Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 27 (2007), 670–684.
67. Young, A., Mittal, D., Stagg, J., Smyth, M.J., Targeting cancer-derived adenosine: new therapeutic approaches. Cancer Discov. 4 (2014), 879–888.
68. Zaretsky, J.M., Garcia-Diaz, A., Shin, D.S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D.Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N. Engl. J. Med. 375 (2016), 819–829.
69. Zhou, X., Yu, S., Zhao, D.M., Harty, J.T., Badovinac, V.P., Xue, H.H., Differentiation and persistence of memory CD8(+) T cells depend on T cell factor 1. Immunity 33 (2010), 229–240.